You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorpromazine
Accession NumberDB00477  (APRD00482)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem]
Structure
Thumb
Synonyms
3-(2-chloro-10H-Phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-Chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Aminazine
Chlorderazin
Chloropromazine
Chlorpromados
Chlorpromazine
Chlorpromazinum
Clorpromazina
Contomin
CPZ
Largactil
N-(3-Dimethylaminopropyl)-3-chlorophenothiazine
Thorazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorprom Tab 100mgTablet111.6 mgOralIcn Canada Ltd.1962-12-311998-08-13Canada
Chlorprom Tab 25mgTablet27.9 mgOralIcn Canada Ltd.1974-12-311998-08-13Canada
Chlorprom Tab 50mgTablet55.8 mgOralIcn Canada Ltd.1962-12-311998-08-13Canada
Chlorpromanyl 20 SyrSolution / drops22.2 mgOralTechnilab Pharma Inc.1983-12-312004-08-03Canada
Chlorpromanyl 40 Drops Syr 44.5mg/mlSyrup44.5 mgOralTechnilab Pharma Inc.1986-12-312006-07-28Canada
Chlorpromazine HCl Inj 25mg/ml USPLiquid25 mgIntramuscular; IntravenousMylan Pharmaceuticals Ulc1994-12-312015-11-03Canada
Chlorpromazine HCl Inj 27.9mg/mlLiquid27.9 mgIntramuscular; IntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Chlorpromazine HCl Inj USPSolution25 mgIntramuscular; IntravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Chlorpromazine Hydrochloride InjectionLiquid27.9 mgIntramuscular; IntravenousSandoz Canada Incorporated1988-12-31Not applicableCanada
Chlorpromazine Tab 25mgTablet27.9 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Chlorpromazine Tablets B.P. 100mgTablet100 mgOralClonmel Healthcare Limited1992-12-311996-09-09Canada
Chlorpromazine Tablets B.P. 25mgTablet25 mgOralClonmel Healthcare Limited1992-12-311996-09-09Canada
Chlorpromazine Tablets B.P. 50mgTablet50 mgOralClonmel Healthcare Limited1992-12-311996-09-09Canada
Largactil 100Liquid100 mgOralSanofi Aventis Canada Inc1963-12-312006-07-28Canada
Largactil 25Liquid25 mgOralSanofi Aventis Canada Inc1960-12-312006-07-28Canada
Largactil 50Solution50 mgIntramuscular; IntravenousAventis Pharma Inc1952-12-312005-08-01Canada
Largactil Drops 40mg/mlSolution / drops40 mgOralSanofi Aventis Canada Inc1952-12-312007-01-30Canada
Largactil Sup 100mgSuppository100 mgRectalSanofi Aventis Canada Inc1952-12-312006-07-28Canada
Novo-chlorpromazine 200mgTablet223.2 mgOralNovopharm Limited1970-12-312005-08-10Canada
Novo-chlorpromazine Tab 10mgTablet11.16 mgOralNovopharm Limited1971-12-312005-08-10Canada
Teva-chlorpromazineTablet50.0 mgOralTeva Canada Limited1967-12-31Not applicableCanada
Teva-chlorpromazineTablet25.0 mgOralTeva Canada Limited1967-12-31Not applicableCanada
Teva-chlorpromazineTablet100 mgOralTeva Canada Limited1967-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo ChlorpromazineTablet55.7 mgOralApotex Inc1976-12-312011-08-05Canada
Apo ChlorpromazineTablet111.4 mgOralApotex Inc1976-12-312011-08-05Canada
Apo ChlorpromazineTablet27.9 mgOralApotex Inc1976-12-312011-08-05Canada
ChlorpromazineTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
ChlorpromazineTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
ChlorpromazineTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralCarilion Materials Management2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralREMEDYREPACK INC.2007-05-23Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralCardinal Health2011-08-03Not applicableUs
Chlorpromazine HydrochlorideInjection25 mg/mLIntramuscularWest Ward Pharmaceutical Corp.1974-07-25Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralTYA Pharmaceuticals1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralREMEDYREPACK INC.2012-10-22Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralREMEDYREPACK INC.2013-03-13Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralClinical Solutions Wholesale, Llc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralMylan Institutional Inc.1994-11-28Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralREMEDYREPACK INC.2010-12-16Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated10 mg/1OralUpsher Smith Laboratories, Inc.2011-08-08Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated10 mg/1OralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralCardinal Health2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralTYA Pharmaceuticals1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralClinical Solutions Wholesale, Llc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralMylan Institutional Inc.1994-11-28Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralREMEDYREPACK INC.2006-11-08Not applicableUs
Chlorpromazine HydrochlorideTablet, film coated25 mg/1OralPhysicians Total Care, Inc.1973-01-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralCardinal Health2011-04-01Not applicableUs
Chlorpromazine HydrochlorideTablet200 mg/1OralREMEDYREPACK INC.2011-08-162016-10-21Us
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralContract Pharmacy Services Pa2010-02-25Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2007-11-20Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralREMEDYREPACK INC.2007-05-04Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralTYA Pharmaceuticals2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated10 mg/1OralMylan Institutional Inc.1994-11-23Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralREMEDYREPACK INC.2006-11-10Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralCardinal Health2011-08-03Not applicableUs
Chlorpromazine HydrochlorideInjection25 mg/mLIntramuscularWest Ward Pharmaceutical Corp.1974-07-25Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralClinical Solutions Wholesale, Llc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralMylan Institutional Inc.1994-11-23Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralContract Pharmacy Services Pa2010-02-25Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralREMEDYREPACK INC.2012-07-20Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated50 mg/1OralREMEDYREPACK INC.2016-11-25Not applicableUs
Chlorpromazine HydrochlorideInjection25 mg/mLIntramuscularTYA Pharmaceuticals1974-07-25Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralMylan Institutional Inc.1994-11-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChlorpromanylTechnilab (Canada)
LargactilSpecia
ThorazineGlaxoSmithKline
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Chlorpromazine hydrochloride
69-09-0
Thumb
  • InChI Key: FBSMERQALIEGJT-UHFFFAOYSA-N
  • Monoisotopic Mass: 354.072424754
  • Average Mass: 355.325
DBSALT000026
Categories
UNIIU42B7VYA4P
CAS number50-53-3
WeightAverage: 318.864
Monoisotopic: 318.095747015
Chemical FormulaC17H19ClN2S
InChI KeyZPEIMTDSQAKGNT-UHFFFAOYSA-N
InChI
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
IUPAC Name
[3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
Pharmacology
IndicationFor the treatment of schizophrenia, control nausea and vomiting, For relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
Structured Indications
PharmacodynamicsChlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Mechanism of actionChlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 1AProteinyes
antagonist
HumanP08908 details
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinyes
antagonist
HumanP35368 details
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Potassium voltage-gated channel subfamily H member 2ProteinunknownNot AvailableHumanQ12809 details
D(1) dopamine receptorProtein groupunknownNot AvailableHumannot applicabledetails
D(3) dopamine receptorProteinunknownNot AvailableHumanP35462 details
D(4) dopamine receptorProteinunknown
binder
HumanP21917 details
D(1B) dopamine receptorProteinunknownNot AvailableHumanP21918 details
5-hydroxytryptamine receptor 2CProteinunknown
binder
HumanP28335 details
5-hydroxytryptamine 2 receptorProtein groupunknown
binder
Humannot applicabledetails
Alpha-1 adrenergic receptorProtein groupunknownNot AvailableHumannot applicabledetails
Alpha-2 adrenergic receptorProtein groupunknownNot AvailableHumannot applicabledetails
Muscarinic acetylcholine receptor M1ProteinunknownNot AvailableHumanP11229 details
Muscarinic acetylcholine receptor M3ProteinunknownNot AvailableHumanP20309 details
Sphingomyelin phosphodiesteraseProteinunknownNot AvailableHumanP17405 details
CalmodulinProteinunknownNot AvailableHumanP62158 details
alpha1-acid glycoproteinProtein groupunknown
binder
Humannot applicabledetails
5-hydroxytryptamine receptor 6Proteinunknown
binder
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
binder
HumanP34969 details
Histamine H4 receptorProteinunknown
binder
HumanQ9H3N8 details
Related Articles
AbsorptionReadily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.
Volume of distribution
  • 20 L/kg
Protein binding> 90% to plasma proteins, primarily albumin
Metabolism

Extensively metabolized in the liver and kidneys. It is extensively metabolized by cytochrome P450 isozymes CYP2D6 (major pathway), CYP1A2 and CYP3A4. Approximately 10 to 12 major metabolite have been identified. Hydroxylation at positions 3 and 7 of the phenothiazine nucleus and the N-dimethylaminopropyl side chain undergoes demethylation and is also metabolized to an N-oxide. In urine, 20% of chlopromazine and its metabolites are excreted unconjugated in the urine as unchanged drug, demonomethylchlorpromazine, dedimethylchlorpromazine, their sulfoxide metabolites, and chlorpromazine-N-oxide. The remaining 80% consists of conjugated metabolites, principally O-glucuronides and small amounts of ethereal sulfates of the mono- and dihydroxy-derivatives of chlorpromazine and their sulfoxide metabolites. The major metabolites are the monoglucuronide of N-dedimethylchlorpromazine and 7-hydroxychlorpromazine. Approximately 37% of the administered dose of chlorpromazine is excreted in urine.

SubstrateEnzymesProduct
Chlorpromazine
hydroxychlorpromazineDetails
Chlorpromazine
Not Available
chlorpromazine-N-oxideDetails
Chlorpromazine
Not Available
dedimethylchlorpromazineDetails
Chlorpromazine
Not Available
demonomethylchlorpromazineDetails
Chlorpromazine
Not Available
N-dedimethylchlorpromazineDetails
Route of eliminationKidneys, ~ 37% excreted in urine
Half life~ 30 hours
ClearanceNot Available
ToxicityAgitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineChlorpromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineChlorpromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chlorpromazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Chlorpromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Chlorpromazine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Chlorpromazine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chlorpromazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acetazolamide.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Chlorpromazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorpromazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Chlorpromazine.Approved
AlbendazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorpromazine.Approved
AldosteroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Chlorpromazine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Chlorpromazine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Chlorpromazine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chlorpromazine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Chlorpromazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Chlorpromazine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorpromazine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Chlorpromazine.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chlorpromazine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Chlorpromazine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Chlorpromazine.Approved
Aminohippuric acidThe serum concentration of Chlorpromazine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Chlorpromazine.Approved, Withdrawn
AmiodaroneChlorpromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved
AmlodipineThe serum concentration of Chlorpromazine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Chlorpromazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Chlorpromazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Chlorpromazine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorpromazine.Approved, Investigational
AmprenavirThe serum concentration of Chlorpromazine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Chlorpromazine.Approved
AnagrelideChlorpromazine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Chlorpromazine.Approved
Aop200704Chlorpromazine may increase the hypotensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chlorpromazine.Approved
ApomorphineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Chlorpromazine.Approved
AprepitantThe serum concentration of Chlorpromazine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Chlorpromazine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.Approved, Investigational
ArotinololChlorpromazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideChlorpromazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherChlorpromazine may increase the QTc-prolonging activities of Artemether.Approved
ArtemisininThe serum concentration of Chlorpromazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Chlorpromazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Articaine.Approved
AsenapineChlorpromazine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Chlorpromazine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Chlorpromazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Chlorpromazine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Chlorpromazine.Approved
AtorvastatinThe serum concentration of Chlorpromazine can be increased when it is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Chlorpromazine can be increased when it is combined with Atovaquone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chlorpromazine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Azaperone.Vet Approved
AzelastineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Chlorpromazine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Chlorpromazine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Chlorpromazine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Chlorpromazine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Chlorpromazine.Approved
BedaquilineChlorpromazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololChlorpromazine may increase the hypotensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Chlorpromazine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Chlorpromazine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Chlorpromazine.Approved
BenzocaineThe serum concentration of Chlorpromazine can be increased when it is combined with Benzocaine.Approved
BenzphetamineChlorpromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Chlorpromazine.Approved
BepridilThe serum concentration of Chlorpromazine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
BetaxololThe metabolism of Chlorpromazine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe serum concentration of Chlorpromazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololChlorpromazine may increase the hypotensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Chlorpromazine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideChlorpromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe serum concentration of Chlorpromazine can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Chlorpromazine.Approved
BoceprevirThe metabolism of Chlorpromazine can be decreased when combined with Boceprevir.Approved
BopindololChlorpromazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
BosentanThe serum concentration of Chlorpromazine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorpromazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpromazine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Chlorpromazine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Chlorpromazine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Chlorpromazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brotizolam.Approved, Withdrawn
BucindololChlorpromazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Chlorpromazine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Chlorpromazine.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Chlorpromazine.Approved, Investigational
BupranololChlorpromazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Chlorpromazine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Chlorpromazine.Approved
BuspironeThe serum concentration of Chlorpromazine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorpromazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpromazine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorpromazine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chlorpromazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chlorpromazine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chlorpromazine.Approved
CandesartanThe serum concentration of Chlorpromazine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Chlorpromazine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Chlorpromazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorpromazine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chlorpromazine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Chlorpromazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carisoprodol.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Chlorpromazine.Approved
CarvedilolThe serum concentration of Chlorpromazine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Chlorpromazine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Chlorpromazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololChlorpromazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CeritinibThe serum concentration of Chlorpromazine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorpromazine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Chlorpromazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Chlorpromazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloroprocaine.Approved
ChloroquineChlorpromazine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Chlorpromazine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Chlorpromazine.Approved
ChlorphentermineChlorpromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Chlorpromazine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Chlorpromazine.Approved
CholecalciferolThe metabolism of Chlorpromazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Chlorpromazine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidChlorpromazine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe serum concentration of Chlorpromazine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cilnidipine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Chlorpromazine.Approved
CimetidineThe serum concentration of Chlorpromazine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Chlorpromazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Chlorpromazine.Approved
CiprofloxacinChlorpromazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideChlorpromazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorpromazine.Approved
CitalopramChlorpromazine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinChlorpromazine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Chlorpromazine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chlorpromazine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Chlorpromazine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chlorpromazine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chlorpromazine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpromazine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Chlorpromazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Chlorpromazine.Approved
CobicistatThe serum concentration of Chlorpromazine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chlorpromazine.Approved
CocaineThe metabolism of Chlorpromazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chlorpromazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorpromazine.Approved
ColforsinThe serum concentration of Chlorpromazine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Chlorpromazine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorpromazine.Approved
CrizotinibChlorpromazine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.Approved
CyclophosphamideThe serum concentration of Chlorpromazine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Chlorpromazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpromazine.Approved
DabrafenibThe serum concentration of Chlorpromazine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Chlorpromazine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chlorpromazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpromazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorpromazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Chlorpromazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Chlorpromazine.Approved, Investigational
DarunavirThe serum concentration of Chlorpromazine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Chlorpromazine.Approved
DasatinibThe serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Chlorpromazine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chlorpromazine.Approved
DeferasiroxThe serum concentration of Chlorpromazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Chlorpromazine.Approved
DelavirdineThe metabolism of Chlorpromazine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
DesloratadineThe serum concentration of Chlorpromazine can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorpromazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Chlorpromazine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Chlorpromazine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Chlorpromazine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Chlorpromazine.Approved, Illicit
DextromethorphanThe serum concentration of Chlorpromazine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chlorpromazine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Chlorpromazine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Chlorpromazine.Approved
DiethylpropionChlorpromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpromazine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chlorpromazine.Approved
DigoxinThe serum concentration of Chlorpromazine can be decreased when it is combined with Digoxin.Approved
DihydroartemisininThe serum concentration of Chlorpromazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Chlorpromazine.Approved, Illicit
DihydroergotamineThe metabolism of Chlorpromazine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpromazine.Illicit
DiltiazemThe metabolism of Chlorpromazine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Chlorpromazine.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Chlorpromazine can be increased when it is combined with Dipyridamole.Approved
DisopyramideChlorpromazine may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chlorpromazine.Approved, Investigational
DofetilideChlorpromazine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronChlorpromazine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneChlorpromazine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Chlorpromazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Chlorpromazine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Doramectin.Vet Approved
DoxazosinThe serum concentration of Chlorpromazine can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Chlorpromazine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpromazine.Approved, Investigational
DoxorubicinThe serum concentration of Chlorpromazine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Chlorpromazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Illicit
DronedaroneChlorpromazine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Drotebanol.Experimental, Illicit
DuloxetineChlorpromazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorpromazine.Approved
EfavirenzThe serum concentration of Chlorpromazine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Chlorpromazine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chlorpromazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Chlorpromazine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Chlorpromazine.Approved
EnalaprilThe serum concentration of Chlorpromazine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalaprilat.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Chlorpromazine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Chlorpromazine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorpromazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Chlorpromazine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chlorpromazine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorpromazine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorpromazine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.Approved
ErgonovineThe serum concentration of Chlorpromazine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Chlorpromazine can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chlorpromazine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
EscitalopramChlorpromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Chlorpromazine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Chlorpromazine.Investigational
EsmololChlorpromazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Chlorpromazine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Chlorpromazine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorpromazine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Chlorpromazine.Approved
EthanolChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorpromazine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpromazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Chlorpromazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorpromazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Chlorpromazine can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Chlorpromazine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorpromazine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chlorpromazine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Chlorpromazine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Chlorpromazine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Chlorpromazine.Approved
FelodipineThe serum concentration of Chlorpromazine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenoldopam.Approved
FentanylThe serum concentration of Chlorpromazine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chlorpromazine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chlorpromazine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fimasartan.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
FlecainideChlorpromazine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flibanserin.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Chlorpromazine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Chlorpromazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineChlorpromazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolChlorpromazine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Chlorpromazine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Chlorpromazine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpromazine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Chlorpromazine.Approved
FluvoxamineThe metabolism of Chlorpromazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
FosamprenavirThe metabolism of Chlorpromazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Chlorpromazine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Chlorpromazine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorpromazine.Approved
FosphenytoinThe metabolism of Chlorpromazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Chlorpromazine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorpromazine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Chlorpromazine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with gabapentin enacarbil.Approved
Gadobenic acidChlorpromazine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Chlorpromazine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chlorpromazine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorpromazine.Approved
GemifloxacinChlorpromazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Chlorpromazine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Chlorpromazine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Chlorpromazine can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Chlorpromazine.Approved
Gramicidin DThe serum concentration of Chlorpromazine can be increased when it is combined with Gramicidin D.Approved
GranisetronChlorpromazine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chlorpromazine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorpromazine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Chlorpromazine can be increased when it is combined with Halofantrine.Approved
HaloperidolChlorpromazine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Chlorpromazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Chlorpromazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Chlorpromazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Chlorpromazine.Approved, Vet Approved
HydrocodoneChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Chlorpromazine.Approved, Illicit
Hydroxyamphetamine hydrobromideChlorpromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Chlorpromazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Chlorpromazine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chlorpromazine.Approved
IbutilideChlorpromazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Chlorpromazine.Approved
IdelalisibThe serum concentration of Chlorpromazine can be increased when it is combined with Idelalisib.Approved
IloperidoneChlorpromazine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Chlorpromazine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Chlorpromazine.Approved
IndenololChlorpromazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Chlorpromazine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chlorpromazine.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Chlorpromazine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chlorpromazine.Approved, Investigational
IsavuconazoniumThe metabolism of Chlorpromazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorpromazine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
IsoniazidThe metabolism of Chlorpromazine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Chlorpromazine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Chlorpromazine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Chlorpromazine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Chlorpromazine.Approved
ItraconazoleThe metabolism of Chlorpromazine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Chlorpromazine.Approved
IvacaftorThe serum concentration of Chlorpromazine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Chlorpromazine.Approved
KetamineThe serum concentration of Chlorpromazine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chlorpromazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Chlorpromazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Chlorpromazine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorpromazine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorpromazine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chlorpromazine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorpromazine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpromazine.Approved
LenvatinibChlorpromazine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpromazine.Approved, Investigational
LevobunololChlorpromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocetirizine.Approved
LevodopaChlorpromazine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinChlorpromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorpromazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Chlorpromazine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Chlorpromazine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chlorpromazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorpromazine.Approved, Investigational
LiothyronineThe serum concentration of Chlorpromazine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Chlorpromazine can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineChlorpromazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Chlorpromazine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Chlorpromazine.Approved
LithiumLithium may increase the neurotoxic activities of Chlorpromazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Chlorpromazine can be increased when it is combined with Lomitapide.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Chlorpromazine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chlorpromazine.Approved
LopinavirChlorpromazine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Chlorpromazine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorpromazine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Chlorpromazine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Chlorpromazine.Approved
LovastatinThe metabolism of Chlorpromazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorpromazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Chlorpromazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineChlorpromazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chlorpromazine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Chlorpromazine.Approved
MebendazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorpromazine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Chlorpromazine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Chlorpromazine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Melperone.Approved
MephedroneChlorpromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineChlorpromazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Chlorpromazine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Chlorpromazine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineChlorpromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Chlorpromazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Chlorpromazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Chlorpromazine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Chlorpromazine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorpromazine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chlorpromazine.Approved
MethotrimeprazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Chlorpromazine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorpromazine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Chlorpromazine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Chlorpromazine.Approved, Illicit, Withdrawn
MetipranololChlorpromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Chlorpromazine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorpromazine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Chlorpromazine.Approved
MetyrosineChlorpromazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Chlorpromazine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Chlorpromazine.Approved
MibefradilThe serum concentration of Chlorpromazine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Chlorpromazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Chlorpromazine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Chlorpromazine.Approved
MirtazapineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Chlorpromazine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Chlorpromazine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe serum concentration of Chlorpromazine can be increased when it is combined with Mizoribine.Investigational
MMDAChlorpromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Chlorpromazine.Approved
ModafinilThe serum concentration of Chlorpromazine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Chlorpromazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Chlorpromazine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpromazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Chlorpromazine.Approved
NafcillinThe serum concentration of Chlorpromazine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorpromazine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
NaltrexoneThe serum concentration of Chlorpromazine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorpromazine.Approved, Investigational
NaringeninThe serum concentration of Chlorpromazine can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Chlorpromazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Chlorpromazine.Approved, Investigational
NefazodoneThe metabolism of Chlorpromazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Chlorpromazine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Chlorpromazine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Chlorpromazine.Approved, Investigational
NetupitantThe serum concentration of Chlorpromazine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Chlorpromazine can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Chlorpromazine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Chlorpromazine.Approved
NicorandilNicorandil may increase the hypotensive activities of Chlorpromazine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Chlorpromazine.Approved
NifedipineThe serum concentration of Chlorpromazine can be decreased when it is combined with Nifedipine.Approved
NilotinibChlorpromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Chlorpromazine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorpromazine.Approved
NisoldipineThe serum concentration of Chlorpromazine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Chlorpromazine.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorpromazine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorpromazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chlorpromazine.Approved
NorethisteroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Chlorpromazine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
OfloxacinChlorpromazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
OlaparibThe metabolism of Chlorpromazine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorpromazine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chlorpromazine.Approved
OmeprazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronChlorpromazine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Opium.Approved, Illicit
OrphenadrineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Chlorpromazine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxybuprocaine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Chlorpromazine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
P-NitrophenolThe serum concentration of Chlorpromazine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Chlorpromazine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Chlorpromazine can be increased when it is combined with Palbociclib.Approved
PaliperidoneChlorpromazine may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Chlorpromazine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Chlorpromazine.Approved, Investigational
PanobinostatThe serum concentration of Chlorpromazine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Chlorpromazine.Approved
ParaldehydeChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Chlorpromazine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Chlorpromazine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.Approved
Peginterferon alfa-2bThe serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololChlorpromazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineChlorpromazine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Chlorpromazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perazine.Investigational
PerflutrenChlorpromazine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Chlorpromazine.Approved
PerindoprilThe serum concentration of Chlorpromazine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Chlorpromazine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Chlorpromazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Chlorpromazine.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorpromazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Chlorpromazine.Approved, Withdrawn
PhenobarbitalThe metabolism of Chlorpromazine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoxyethanol.Approved
PhentermineChlorpromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phentolamine.Approved
PhenytoinThe metabolism of Chlorpromazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideChlorpromazine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Chlorpromazine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Chlorpromazine.Approved
PiribedilThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorpromazine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Chlorpromazine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpromazine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chlorpromazine.Approved
PosaconazoleThe metabolism of Chlorpromazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololChlorpromazine may increase the hypotensive activities of Practolol.Approved
PramipexoleChlorpromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorpromazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Chlorpromazine can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorpromazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prilocaine.Approved
PrimaquineChlorpromazine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Chlorpromazine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Chlorpromazine can be increased when it is combined with Probenecid.Approved
ProcainamideChlorpromazine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorpromazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe serum concentration of Chlorpromazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Chlorpromazine.Approved
PropafenoneThe serum concentration of Chlorpromazine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Chlorpromazine.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorpromazine.Approved
PSD502The risk or severity of adverse effects can be increased when Chlorpromazine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Chlorpromazine.Approved
PyrimethamineThe serum concentration of Chlorpromazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Chlorpromazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Chlorpromazine can be increased when it is combined with Quercetin.Experimental
QuetiapineChlorpromazine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorpromazine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Chlorpromazine.Approved, Investigational
QuinidineChlorpromazine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineChlorpromazine may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Chlorpromazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorpromazine.Approved
RanitidineThe serum concentration of Chlorpromazine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorpromazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorpromazine.Approved
ReboxetineThe serum concentration of Chlorpromazine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Chlorpromazine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Chlorpromazine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Chlorpromazine.Investigational
ReserpineThe serum concentration of Chlorpromazine can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Chlorpromazine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Chlorpromazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Chlorpromazine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorpromazine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Chlorpromazine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Chlorpromazine.Approved
RisperidoneChlorpromazine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ritanserin.Investigational
RitobegronChlorpromazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Chlorpromazine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpromazine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorpromazine.Approved
RolapitantThe serum concentration of Chlorpromazine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chlorpromazine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Romifidine.Vet Approved
RopiniroleChlorpromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Chlorpromazine.Approved
RotigotineChlorpromazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorpromazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
SaquinavirChlorpromazine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Chlorpromazine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorpromazine.Approved, Vet Approved
SelegilineThe serum concentration of Chlorpromazine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chlorpromazine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Chlorpromazine.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Chlorpromazine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
SildenafilThe metabolism of Chlorpromazine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.Approved
SiltuximabThe serum concentration of Chlorpromazine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Chlorpromazine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Chlorpromazine can be increased when it is combined with Simvastatin.Approved
SinefunginThe serum concentration of Chlorpromazine can be increased when it is combined with Sinefungin.Experimental
SirolimusThe serum concentration of Chlorpromazine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chlorpromazine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chlorpromazine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Chlorpromazine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
SotalolChlorpromazine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorpromazine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Chlorpromazine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chlorpromazine.Experimental
SpironolactoneThe serum concentration of Chlorpromazine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Chlorpromazine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Chlorpromazine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Chlorpromazine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Chlorpromazine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfadoxine.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Chlorpromazine.Approved
SulfametopyrazineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfinpyrazoneThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Chlorpromazine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
SuvorexantChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Chlorpromazine can be decreased when it is combined with Tacrolimus.Approved, Investigational
tafenoquineThe serum concentration of Chlorpromazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chlorpromazine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Chlorpromazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorpromazine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chlorpromazine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorpromazine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Chlorpromazine.Investigational, Withdrawn
TelaprevirThe metabolism of Chlorpromazine can be decreased when combined with Telaprevir.Approved
TelavancinChlorpromazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinChlorpromazine may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe serum concentration of Chlorpromazine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorpromazine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpromazine.Approved
TenofovirThe metabolism of Chlorpromazine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Chlorpromazine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Chlorpromazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Chlorpromazine.Approved
TerfenadineThe serum concentration of Chlorpromazine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Chlorpromazine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Chlorpromazine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorpromazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrodotoxin.Investigational
ThalidomideChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Chlorpromazine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Chlorpromazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Chlorpromazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpromazine.Approved
TiclopidineThe metabolism of Chlorpromazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Chlorpromazine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Chlorpromazine.Approved
TipranavirThe metabolism of Chlorpromazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Chlorpromazine.Approved
TocilizumabThe serum concentration of Chlorpromazine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chlorpromazine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorpromazine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Chlorpromazine.Approved
ToremifeneChlorpromazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Chlorpromazine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chlorpromazine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorpromazine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Chlorpromazine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chlorpromazine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorpromazine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triazolam.Approved
TrifluoperazineThe serum concentration of Chlorpromazine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Chlorpromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
TroleandomycinThe serum concentration of Chlorpromazine can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chlorpromazine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chlorpromazine.Approved
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Chlorpromazine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorpromazine.Approved, Investigational
VandetanibChlorpromazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Chlorpromazine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chlorpromazine.Approved
VemurafenibThe serum concentration of Chlorpromazine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Chlorpromazine.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Chlorpromazine.Approved
VerapamilThe metabolism of Chlorpromazine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Chlorpromazine.Approved
VinblastineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorpromazine.Approved, Investigational
VincristineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Chlorpromazine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chlorpromazine.Approved
VoriconazoleThe metabolism of Chlorpromazine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Chlorpromazine.Approved
XylazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Chlorpromazine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chlorpromazine.Approved
ZimelidineThe serum concentration of Chlorpromazine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneChlorpromazine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorpromazine.Approved, Investigational
ZolpidemChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zotepine.Approved
ZuclopenthixolChlorpromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Charpentier, P.; U S . Patent 2,645,640; July 14, 1953; assigned to Societe des Usines Chimiques Rhone-Poulenc, France.

US2645640
General References
  1. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10;361(9369):1581-9. [PubMed:12747876 ]
External Links
ATC CodesN05AA01
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9757
Blood Brain Barrier+0.9795
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.787
P-glycoprotein inhibitor IInhibitor0.7164
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.7557
CYP450 2C9 substrateNon-substrate0.7617
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6477
CYP450 1A2 substrateInhibitor0.9305
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.9422
CYP450 2C19 inhibitorInhibitor0.5512
CYP450 3A4 inhibitorNon-inhibitor0.9375
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6601
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9309
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3196 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9536
hERG inhibition (predictor II)Inhibitor0.787
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Actavis mid atlantic llc
  • Pharmaceutical assoc inc div beach products
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Sandoz inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alpharma us pharmaceuticals division
  • Abbott laboratories pharmaceutical products div
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lederle laboratories div american cyanamid co
  • Purepac pharmaceutical co
  • Private formulations inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • West ward pharmaceutical corp
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
TabletOral111.4 mg
TabletOral55.7 mg
TabletOral111.6 mg
TabletOral27.9 mg
TabletOral55.8 mg
Solution / dropsOral22.2 mg
SyrupOral44.5 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
LiquidIntramuscular; Intravenous25 mg
SolutionIntramuscular; Intravenous25 mg
InjectionIntramuscular25 mg/mL
TabletOral200 mg/1
TabletOral50 mg/1
Tablet, sugar coatedOral10 mg/1
Tablet, sugar coatedOral100 mg/1
Tablet, sugar coatedOral200 mg/1
Tablet, sugar coatedOral25 mg/1
Tablet, sugar coatedOral50 mg/1
LiquidIntramuscular; Intravenous27.9 mg
TabletOral25 mg
TabletOral50 mg
LiquidOral100 mg
LiquidOral25 mg
SolutionIntramuscular; Intravenous50 mg
Solution / dropsOral40 mg
SuppositoryRectal100 mg
TabletOral223.2 mg
TabletOral11.16 mg
TabletOral100 mg
TabletOral25.0 mg
TabletOral50.0 mg
Prices
Unit descriptionCostUnit
Chlorpromazine 25 mg/ml amp8.04USD ml
ChlorproMAZINE HCl 200 mg tablet1.19USD tablet
Chlorpromazine 200 mg tablet1.05USD tablet
ChlorproMAZINE HCl 100 mg tablet0.84USD tablet
ChlorproMAZINE HCl 50 mg tablet0.73USD tablet
ChlorproMAZINE HCl 25 mg tablet0.55USD tablet
Chlorpromazine 100 mg tablet0.39USD tablet
ChlorproMAZINE HCl 10 mg tablet0.37USD tablet
Chlorpromazine 10 mg tablet0.32USD tablet
Chlorpromazine 50 mg tablet0.3USD tablet
Chlorpromazine 25 mg tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point177-178Charpentier, P.; U S . Patent 2,645,640; July 14, 1953; assigned to Societe des Usines Chimiques Rhone-Poulenc, France
boiling point200-205 °C at 8.00E-01 mm HgPhysProp
water solubility2.55 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.41AVDEEF,A (1995)
logS-5.01ADME Research, USCD
Caco2 permeability-4.7ADME Research, USCD
pKa9.3 (at 25 °C)HANSCH,C & LEO,AJ (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00417 mg/mLALOGPS
logP5.18ALOGPS
logP4.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.76 m3·mol-1ChemAxon
Polarizability35.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.36 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9231000000-ed14fee152701eacf689View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263 ]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
  7. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
  8. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995 Aug;120(3):365-8. [PubMed:8524985 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438 ]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134 ]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
  2. Church MK, Young KD: The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol. 1983 Apr;78(4):671-9. [PubMed:6189542 ]
  3. Johnson HG, Miller MD: Inhibition of histamine release and ionophore-induced calcium flux in rat mast cells by lidocaine and chlorpromazine. Agents Actions. 1979 Aug;9(3):239-43. [PubMed:91313 ]
  4. Palmer GC, Wagner HR, Palmer SJ, Manian AA: Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol. Arch Int Pharmacodyn Ther. 1978 Jun;233(2):314-25. [PubMed:687395 ]
  5. Ruffolo RR, Patil PN: Kinetics of blockade of different receptors by chlorpromazine in rabbit stomach strips. Eur J Pharmacol. 1978 Mar 15;48(2):151-7. [PubMed:25190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wu K, Kathofer S, Katus HA, Schoels W, Kiehn J, Karle CA: The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol. 2003 Jun;139(3):567-74. [PubMed:12788816 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. [PubMed:8104554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995 Aug;120(3):365-8. [PubMed:8524985 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. [PubMed:8104554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 2AP28223 Details
5-hydroxytryptamine receptor 2BP41595 Details
5-hydroxytryptamine receptor 2CP28335 Details
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70. [PubMed:6135146 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Bylund DB, Ray-Prenger C, Murphy TJ: Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther. 1988 May;245(2):600-7. [PubMed:2835476 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl). 2005 Apr;178(4):451-60. Epub 2004 Oct 13. [PubMed:15765260 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl). 2005 Apr;178(4):451-60. Epub 2004 Oct 13. [PubMed:15765260 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sphingomyelin phosphodiesterase activity
Specific Function:
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.
Gene Name:
SMPD1
Uniprot ID:
P17405
Molecular Weight:
69751.3 Da
References
  1. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, Satoyoshi E: Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem. 1985 Dec;98(6):1669-79. [PubMed:2419314 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Marshak DR, Lukas TJ, Watterson DM: Drug-protein interactions: binding of chlorpromazine to calmodulin, calmodulin fragments, and related calcium binding proteins. Biochemistry. 1985 Jan 1;24(1):144-50. [PubMed:2986673 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Components:
NameUniProt IDDetails
Alpha-1-acid glycoprotein 1P02763 Details
Alpha-1-acid glycoprotein 2P19652 Details
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF: Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001 Mar;59(3):427-33. [PubMed:11179435 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  3. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67(2):175-84. [PubMed:10901285 ]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67(2):175-84. [PubMed:10901285 ]
  2. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Nasello AG, Gidali D, Felicio LF: A comparative study of the anticholinesterase activity of several antipsychotic agents. Pharmacol Biochem Behav. 2003 Jul;75(4):895-901. [PubMed:12957233 ]
  2. Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003 Feb;92(2):100-4. [PubMed:12747580 ]
  3. Spinedi A, Pacini L, Limatola C, Luly P, Farias RN: A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine. Biochem J. 1991 Sep 1;278 ( Pt 2):461-3. [PubMed:1654884 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214 ]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920 ]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23